PharmaBiome

Executive Summary

PharmaBiome is a Switzerland-based pre-clinical microbiome company founded in 2016. The company focuses on decoding the gut microbiome as a network of interconnected metabolic functions essential for host health. By targeting the common denominator underlying microbiome function, PharmaBiome aims to develop rationally designed therapeutics that restore ecological balance in the gut. Their approach emphasizes the metabolic interdependencies within microbial communities, potentially offering a differentiated strategy for treating gastrointestinal and systemic diseases. As a pre-clinical entity, the company is currently advancing its lead candidates through early development stages, with a priority on completing IND-enabling studies and initiating first-in-human trials. The microbiome space holds promise but also faces challenges in clinical translation; PharmaBiome's unique metabolic network perspective may help address these hurdles. Key upcoming milestones include lead candidate selection, toxicology study initiation, and potential partnership agreements to fund further R&D. The company's success will depend on scientific validation and execution of its development plan.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate nomination for first therapeutic program40% success
• Q2 2027Initiation of IND-enabling toxicology studies35% success
• H1 2027Announcement of strategic partnership or funding round50% success